Sign In
Buy AGLE
$12.01
+0 (+0%)
At Close: Feb 26, 2024
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Expected to Announce Earnings of -$0.29 Per Share
08:38am, Monday, 15'th Nov 2021 Dakota Financial News
Brokerages expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to post earnings per share of ($0.29) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Aeglea BioTherapeutics earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.34). Aeglea BioTherapeutics reported earnings of ($0.34) per share during []
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
08:30am, Thursday, 05'th Aug 2021
AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so
AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative
Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer
08:30am, Thursday, 08'th Jul 2021
AUSTIN, Texas, July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative
AUSTIN, Texas, June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative
Aeglea BioTherapeutics: Late-Stage Enzyme Therapeutic Biotech Approaches Promising Phase 3 Data Announcement
11:04am, Wednesday, 19'th May 2021
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases with limited treatment options. Aeglea's pipeline consists of two clin
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
08:30am, Monday, 10'th May 2021
AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so
AUSTIN, Texas, May 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
04:30pm, Thursday, 01'st Apr 2021
AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peo
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
08:30am, Thursday, 18'th Mar 2021
AUSTIN, Texas, March 18, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative
Aeglea (AGLE) Upgraded to Buy: Here's Why
12:47pm, Wednesday, 30'th Dec 2020
Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
04:05pm, Thursday, 17'th Dec 2020
AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative s
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
07:30am, Tuesday, 01'st Dec 2020
AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative s
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
04:30pm, Tuesday, 17'th Nov 2020
AUSTIN, Texas, Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative
Steven Cohen Jumps Back Into Aeglea BioTherapeutics
03:10pm, Friday, 30'th Oct 2020
Billionaire investor Steven Cohen (Trades, Portfolio) revealed a new stake in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) late last week.
